The overall long term goal of this Imaging Core is to identify structural, perfusion, and metabolic changes in the brain that predict future cognitive decline and conversion to dementia. The overall approach will be to initially study healthy elders ands age/gender matched patients with well-characterized dementia associated with Alzheimer's disease and Frontotemporal dementia using a newly acquired 4 Tesla Bruker/Siemens MRI/MRS scanner, which will be optimized for investigation of neurodegenerative disease. These initial studies will provide imaging characteristics of established dementia. We will also study a group of subjects with MCl-Peterson criteria. In subsequent years we will study increasing numbers of subjects with MCI subtypes and MCl-Peterson who likely represent early stages of AD and FTD and who are expected to ultimately convert to dementia. All subjects will be recruited and evaluated by the Clinical Core.

Public Health Relevance

Alzheimer's disease affects millions of Americans, and the incidence and prevalence are growing as people get older. MRI imaging provides unique information concerning the changes in the brain which occur in demented subjects, as well as in the early stages of the disease. Imaging also helps identify other processes which lead to cognitive impairment. Thus, state of the art imaging is a critical aspect of this ADRC.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG023501-10
Application #
8458090
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$128,045
Indirect Cost
$46,278
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
McKeever, Paul M; Schneider, Raphael; Taghdiri, Foad et al. (2018) MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. Mol Neurobiol 55:8826-8841
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Iaccarino, Leonardo; Tammewar, Gautam; Ayakta, Nagehan et al. (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin 17:452-464
Wang, Chengzhong; Najm, Ramsey; Xu, Qin et al. (2018) Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 24:647-657
Bettcher, Brianne M; Johnson, Sterling C; Fitch, Ryan et al. (2018) Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. J Alzheimers Dis 62:385-397
Kim, Eun-Joo; Brown, Jesse A; Deng, Jersey et al. (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960-2971

Showing the most recent 10 out of 590 publications